PortfoliosLab logoPortfoliosLab logo
KPTI vs. SES
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KPTI vs. SES - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and SES AI Corp (SES). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KPTI achieves a 15.49% return, which is significantly higher than SES's -37.78% return.


KPTI

1D
-6.39%
1M
-1.62%
YTD
15.49%
6M
44.31%
1Y
89.31%
3Y*
-36.47%
5Y*
-43.70%
10Y*
-23.75%

SES

1D
-5.08%
1M
20.53%
YTD
-37.78%
6M
-46.67%
1Y
7.69%
3Y*
-17.44%
5Y*
-35.53%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

KPTI vs. SES - Yearly Performance Comparison


2026 (YTD)20252024202320222021
KPTI
Karyopharm Therapeutics Inc.
15.49%-27.45%-21.82%-74.56%-47.12%-53.24%
SES
SES AI Corp
-37.78%-17.81%19.67%-41.90%-68.34%-7.44%

Correlation

The correlation between KPTI and SES is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Mar 2, 2021

0.18

Fundamentals

Market Cap

KPTI:

$210.08M

SES:

$372.78M

EPS

KPTI:

-$13.00

SES:

-$0.22

PS Ratio

KPTI:

0.84

SES:

16.95

Total Revenue (TTM)

KPTI:

$151.12M

SES:

$21.92M

Gross Profit (TTM)

KPTI:

$145.13M

SES:

$7.97M

EBITDA (TTM)

KPTI:

-$93.05M

SES:

-$68.11M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KPTI vs. SES — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI
KPTI Risk / Return Rank: 7373
Overall Rank
KPTI Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
KPTI Sortino Ratio Rank: 7676
Sortino Ratio Rank
KPTI Omega Ratio Rank: 7171
Omega Ratio Rank
KPTI Calmar Ratio Rank: 7474
Calmar Ratio Rank
KPTI Martin Ratio Rank: 7575
Martin Ratio Rank

SES
SES Risk / Return Rank: 4848
Overall Rank
SES Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
SES Sortino Ratio Rank: 5353
Sortino Ratio Rank
SES Omega Ratio Rank: 5252
Omega Ratio Rank
SES Calmar Ratio Rank: 4545
Calmar Ratio Rank
SES Martin Ratio Rank: 4444
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. SES - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and SES AI Corp (SES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KPTISESDifference
Sharpe ratioReturn per unit of total volatility

+0.88

Sortino ratioReturn per unit of downside risk

+1.05

Omega ratioGain probability vs. loss probability

1.22

1.11

+0.11

Calmar ratioReturn relative to maximum drawdown

1.86

0.10

+1.75

Martin ratioReturn relative to average drawdown

4.59

0.17

+4.42

KPTI vs. SES - Sharpe Ratio Comparison

The current KPTI Sharpe Ratio is 0.95, which is higher than the SES Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of KPTI and SES, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KPTISESDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.95

0.07

+0.88

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.46

-0.31

-0.15

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.27

-0.31

+0.05

Drawdowns

KPTI vs. SES - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, roughly equal to the maximum SES drawdown of -97.58%. Use the drawdown chart below to compare losses from any high point for KPTI and SES.


Loading charts...

Drawdown Indicators


KPTISESDifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

-97.58%

-1.92%

Max Drawdown (1Y)

Largest decline over 1 year

-48.36%

-74.08%

+25.72%

Max Drawdown (3Y)

Largest decline over 3 years

-89.32%

-91.41%

+2.09%

Max Drawdown (5Y)

Largest decline over 5 years

-98.36%

-97.58%

-0.78%

Max Drawdown (10Y)

Largest decline over 10 years

-99.15%

Current Drawdown

Current decline from peak

-98.80%

-89.95%

-8.85%

Average Drawdown

Average peak-to-trough decline

-75.28%

-65.74%

-9.54%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.53%

44.55%

-25.02%

Volatility

KPTI vs. SES - Volatility Comparison

The current volatility for Karyopharm Therapeutics Inc. (KPTI) is 24.86%, while SES AI Corp (SES) has a volatility of 27.91%. This indicates that KPTI experiences smaller price fluctuations and is considered to be less risky than SES based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KPTISESDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.86%

27.91%

-3.05%

Volatility (6M)

Calculated over the trailing 6-month period

62.32%

76.82%

-14.50%

Volatility (1Y)

Calculated over the trailing 1-year period

94.32%

107.24%

-12.92%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.91%

114.56%

-19.65%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.51%

111.60%

-25.09%

Dividends

KPTI vs. SES - Dividend Comparison

Neither KPTI nor SES has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

KPTI vs. SES - Financials Comparison

This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and SES AI Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M20222023202420252026
35.07M
6.71M
(KPTI) Total Revenue
(SES) Total Revenue
Values in USD except per share items

Frequently Asked Questions


KPTI and SES have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SES has higher volatility (27.91%) compared to KPTI (24.86%). In terms of maximum drawdown, KPTI dropped -99.50% vs SES's -97.58%.

KPTI currently has the higher Sharpe Ratio (0.95 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KPTI and SES

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer